| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $103.8M | — | -10.7% |
| SG&A Expense | $33.5M | — | +14.2% |
| Operating Income | -$137.4M | — | +5.6% |
| Net Income | -$128.4M | — | +3.4% |
| EPS (Basic) | -$0.69 | — | +11.5% |
| EPS (Diluted) | -$0.69 | — | +11.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $387.6M | +88.8% | +580.7% |
| Short-term Investments | $600.1M | -9.4% | -21.1% |
| Current Assets | $1.02B | +13.6% | +16.4% |
| Total Assets | $1.27B | +10.6% | -0.4% |
| Current Liabilities | $110.2M | +12.0% | +19.9% |
| Total Liabilities | $339.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$131.2M | — | +0.2% |
| Capital Expenditures | $2.5M | — | -51.4% |
| Investing Cash Flow | $94.5M | — | +403.8% |
| Financing Cash Flow | $219.0M | — | +5922.5% |
| Free Cash Flow | -$133.7M | — | +2.1% |
| +128.7% |
| Stockholders' Equity | $926.1M | -8.6% | -17.5% |